Figure 5.
In vivo anti-tumour efficacy in s.c. implanted models. Animals were treated with vehicle or with PHA-848125 at 40 mg·kg−1 BID for 10 consecutive days. (A) Tumour growth curves of U251 glioma model, treatment started on day 14; (B) tumour growth curves of U87MG glioma model, treatment started on day 8. For ex vivo analysis, 5 days after the last treatment, U87MG tumours from four control and four treated animals were excised. (C) Evaluation of ATG4A and P-AKT expression by Western blot analysis; (D) evaluation of ATG4A expression by immunohistochemistry. Images of the same tumours stained with H&E are reported. Morphological analysis allowed counting mitotic figures (indicated by arrows): CTR > 100/field 200×; PHA 848125 < 10/field 200×.